Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number by Buors, C et al.
LETTER TO THE EDITOR
Clonal evolution in UKE-1 cell line leading to an increase in
JAK2 copy number
Blood Cancer Journal (2012) 2, e66; doi:10.1038/bcj.2012.11;
published online 13 April 2012
The JAK2 V617F mutation is present in the vast majority of
polycythemia vera patients, and in about half of patients
with primary myeloﬁbrosis and essential thrombocythemia.
1 A
correlation between MPN disease phenotype and the proportion
of JAK2 V617F mutant alleles
2,3 has lead to the need for sensitive
and reproducible molecular techniques to assess the so-called
JAK2 V617F allele burden in patient samples. A 2009 multicenter
study conducted by Lippert et al.
4 assessed the concordance of
JAK2 V617F allele burden quantitation from various diagnostic
laboratories. The study demonstrated the importance of using
well-deﬁned and accurate standards to calibrate JAK2 V617F
quantitative assays. To that end, the authors suggested the use of
plasmid DNA dilutions along with a known genomic DNA sample
as an internal control to allow for the most precise quantiﬁcation
of JAK2 V617F allele burden. As an alternative to plasmids, the
diploid UKE-1 cell line, having two copies of mutated JAK2 per cell,
was suggested as a useful genomic DNA standard.
4
There are several JAK2 V617F-positive cell lines derived from
patients with history of myeloproliferative or myelodysplasic
disorders (HEL, MB-02, MUTZ-8, SET-2 and UKE-1) that differ in
number of JAK2 mutant alleles. These cell lines are good research
tools for elucidating the pathobiology of MPN,
5 and are potential
standard material as well. However, HEL cells have more than two
copies of JAK2 and should not be used as a standard for
quantiﬁcation of JAK2 V617F allele burden.
3,4 The UKE-1 cell line
has recently been shown to be homozygous for the JAK2 V617F
mutation
4,5 and may therefore be a useful as a genomic DNA
standard. UKE-1 was derived from an essential thrombocythemia
patient transformed into acute leukemia in 1997.
6 Phenotypic
analysis of leukemic cells revealed coexpression of myeloid
and endothelial antigens. Cytogenetic analysis of cells showed
biclonality with the following karyotype: 48,XX,þ8,þ14[14]/45,
XX,-7,del(11)(p14)[8]. UKE-1 cells were cultured in Iscove modiﬁed
Dulbecco medium supplemented with 10% fetal calf serum, 10%
horse serum and 1mM hydrocortisone. Morphologically, UKE-1
cells were described as heterogeneous, with coexistence of large,
adherent cells with prominent vacuoles and smaller nonadherent
cells.
6
Here, we show that UKE-1 cells in our hands underwent clonal
evolution during in vitro culture, leading to an increase of JAK2
gene copies. Use of these cells as a standard would cause an
underestimation of the JAK2 V617F allele burden.
The UKE-1 cells used in this study had been cultured for 5
months, frozen for 16 months, then thawed. We then cultivated
the UKE-1 cells and a human myeloid cell line, HL60, for 3 weeks
before making serial dilutions of UKE-1 in HL60 (100% UKE-1
through 0% UKE-1). This widely used human myeloid cell line
derives from leukocytes of a patient with acute promyelocytic
leukemia in 1979. Initial cytogenetic analysis revealed 75% of
aneuploid cells (44 chromosomes) with structural anomalies
on chromosomes 7, 9, 10 and number anomalies on chromo-
somes 5, 8, 18, X.
7 The cell mixtures were washed twice in
1  phosphate-buffered saline and pelleted. Genomic DNA was
extracted with the FlexiGene DNA kit (Qiagen, Courtaboeuf,
France), and JAK2 V617F quantiﬁcation was performed using the
plasmid based JAK2 Mutaquant kit (Ipsogen SA, Marseille, France)
according to manufacturer recommendations.
Throughout the range of dilutions, we found that the measured
JAK2 V617F allele burden in the UKE-1/HL60 mixtures was
consistently higher than expected (Figure 1). Similar ﬁndings
were found in another lab. It was found that the JAK2 V617F allele
burden was consistently overestimated when Mutaquant kit was
used on a range of dilution of the line UKE-1: 2.4% for 1%, 67% for
50% in mean (Cassinat, personal data). One possible explanation
for this discrepancy is an abnormal JAK2 copy number in one of
the cell lines. We therefore performed conventional and molecular
cytogenetic analysis of the HL60 and UKE-1 cells. Karyotypes were
determined using standard cytogenetic techniques and described
according to the International System for Human Cytogenetic
Nomenclature (ISCN 2009).
8 In order to assess JAK2 copy
number, ﬂuorescence in situ hybridization with bacterial artiﬁcial
chromosomes (FISH-BAC) was performed as previously described.
9
A BAC-targeting JAK2 (RP11-982A21 on 9p24.1 band) labeled in
SpectrumGreen (Abbott, Rungis, France) and a reference BAC
(RP11-115G2 located on 9p21.2) labeled in SpectrumOrange
(Abbott) were applied to metaphase preparations and analyzed.
The karyotype of the HL60 cell line was 45,X,del(3)
(p2?),add(5)(q2?3),der(8)t(4;8)(q2?;q24),del(9)(p1?2),del(10)(p1?2),
add(11)(q2?3),i(13)(q10),add(17)(p11),del(18)(q1?)[22] (data not
shown). FISH-BAC with JAK2 probe found an interstitial deletion
of chromosome 9 without JAK2 deletion (data not shown) in HL60
lineage.
Cytogenetic analysis of UKE-1 revealed two clones: a pseudo-
diploid clone (previously observed in 2008 in our lab) (Figure 2a)
and a tetraploid clone (observed for the ﬁrst time) (Figure 2b).
Figure 1. Measured versus expected JAK2 V617F percentage. Serial
dilutions of UKE-1 cells (supposedly homozygous for mutant JAK2
V617F) in HL60 cells (homozygous for wild-type JAK2) were made
and the percentage of JAK2 V617F in each dilution was quantiﬁed
using the JAK2 Mutaquant Ipsogen kit. For each dilution, the
measured JAK2 V617F percentage was signiﬁcantly greater than the
theoretical ratio shown by the dotted line (P¼0.002).
Citation: Blood Cancer Journal (2012) 2, e66; doi:10.1038/bcj.2012.11
& 2012 Macmillan Publishers Limited All rights reserved 2044-5385/12
www.nature.com/bcjThe karyotype of UKE-1 was 46,XX,-7,þ8,del(11)(p1?1p1?3),del
(20q)[12]/92,idemx2,del(9)(q2?1)[8]. The tetraploid clone had three
normal chromosomes 9 and a derivative chromosome 9 having a
partial deletion of the long arm. FISH-BAC analysis showed the
expected two copies of JAK2 in the pseudo-diploid clone (data not
shown) and ﬁve copies of JAK2 in the tetraploid clone: one copy
on each of the three normal chromosomes 9 and two copies of
JAK2 on abnormal chromosome 9 (Figure 2c). As a consequence,
there is an unbalanced ratio of wild-type JAK2 and JAK2 V617F
within the quantiﬁcation standard, leading to an underestimation
of the JAK2 mutational load when using this UKE-1 cell line as the
standard in the analysis of patient samples.
These results highlight the possibility of clonal evolution of the
UKE-1 cell line with an increase in JAK2 gene copy number. The
cell line has deviated following culture in our hands because the
tetraploid clone was not present when supplying in 2008 and only
two copies of JAK2 where detectable at this time. Mechanisms of
this genetic instability may be related to an excessive reactive
oxygen species production that promotes DNA double-strand
breaks and altered repair, as this has been reported in several
myeloid diseases and cell lines.
10 In MPN, it has been shown that
the JAK2 V617F mutation induces an increase in spontaneous
homologous recombination leading to a hyperrecombination
state.
11 JAK2 V617F mutation may also affect p53 response to DNA
damage.
12
Several clinical studies show that measuring the JAK2 V617F
allele burden may be important to assess prognosis and adjust
treatment in MPN patients.
2,3,13,14 Accurate quantiﬁcation of allele
burden requires a well-deﬁned genetic standard for calibration.
Besides, cooperative works are underway to standardize and
harmonize the q-PCR techniques. This study shows that using the
UKE-1 cell line as a standard for JAK2 V617F quantiﬁcation must be
avoided, as cells in culture can acquire multiple copies of
the JAK2 gene.
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